Company Profile

Abilita Bio Inc
Profile last edited on: 7/23/2021            CAGE: 77UL8            UEI: DEYUQFS2MLT5

Improving intrinsic properties of GPCR and ion channel drug targets to develop new protein-based methods: lead to novel, high-quality antibody or small-molecule leads
Year Founded
1st Awd Year
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6888 Nancy Ridge Drive
San Diego, CA 92117
   (858) 366-5435
Multiple Locations:   
Congressional District:   52
County:   San Diego

Public Profile

Abilita Bio is a biotechnology company - an alumni of JLabs San Diego - addressing enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) and ion channels, including G Protein Coupled Receptors (GPCRs) and ion channels. The firm has established research collaborations with global pharmaceutical companies to advance their internal drug discovery programs targeting GPCRs and ion channels and continues to extend the EMP™ platform into new applications through multiple risk-sharing collaborations with biotechnology industry partners, while leveraging the EMP™ platform to fuel a robust internal drug discovery pipeline focused on treating cancer and chronic pain.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Mauro Mileni -- Founder President and CEO

  Alexander Alexandrov -- Princpal Scientist

  Rosario B Billetta

  Christopher B Bolt -- VP Innovation

  Louis J Cantolupo -- Business Development

  Lynda Groocock

  Heather Pascual

  Dario Ranieri -- Research Associate

  Chris Roth -- Vice President

SBIR firms in the news

There are no news available.